ATOSSA THERAPEUTICS, INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $1.8K | $40.1K | $632.6K | $481.8K | $1.5K |
| Cost of Revenue | — | — | — | $132.4K | $0 | $345.5K | $35.7K | $5.2K |
| Gross Profit | — | — | — | $-130.7K | $40.1K | $137.1K | $416.2K | $-95.7K |
| Gross Margin | — | — | — | -7,431.9% | 100.0% | 21.7% | 86.4% | -6,379.3% |
| Operating Expenses | ||||||||
| Research & Development | $4.2M | $2.3M | $770.4K | $2.4M | $1.1M | $1.1M | $2.0M | — |
| SG&A Expense | $7.2M | $4.9M | $6.5M | $8.8M | $8.1M | $8.6M | $3.0M | $3.2M |
| Operating Income | $-11.4M | $-7.6M | $-8.0M | $-12.8M | $-12.2M | $-10.8M | $-5.1M | $-3.4M |
| Operating Margin | — | — | — | -725,746.2% | -30,323.0% | -1,704.9% | -1,052.0% | -228,612.7% |
| Interest Expense | — | — | — | — | $15.8K | $360 | $12.0K | $18.0K |
| Pretax Income | $-11.4M | $-8.1M | $-6.4M | $-12.8M | $-12.2M | $-10.8M | $-5.1M | $-3.4M |
| Income Tax Expense | $0 | $0 | — | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-11.4M | $-8.1M | $-6.4M | $-15.8M | $-14.7M | $-10.8M | $-5.1M | $-3.4M |
| Net Margin | — | — | — | -896,491.6% | -36,518.8% | -1,704.9% | -1,054.3% | -229,484.5% |
| EPS (Basic) | $-5.50 | $-10.97 | $-2.16 | $-8.31 | $-0.61 | $-0.70 | $-0.41 | $-0.38 |
| EPS (Diluted) | $-5.50 | $-10.97 | $-2.16 | $-8.31 | $-0.61 | $-0.70 | $-0.41 | $-0.38 |
| Shares Outstanding (Basic) | 5.8M | 2.7M | 3.8M | 2.2M | 24.6M | 18.6M | 12.9M | 11.3M |
| Shares Outstanding (Diluted) | 5.8M | 2.7M | 3.8M | 2.2M | 24.6M | 18.6M | 12.9M | 11.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |